Table 2.
Pulmonary Function of TEA Clusters in YCAAD Cohort
| Control Subjects (n = 12) | Cluster 1 (n = 34) | Cluster 2 (n = 19) | Cluster 3 (n = 47) | P Value | |
|---|---|---|---|---|---|
| FEV1, % of predicted value | |||||
| Pre–β2-agonist use | 96 ± 11 | 73 ± 24 | 76 ± 22 | 86 ± 22 | 0.006 |
| Post–β2-agonist use | 98 ± 14 | 80 ± 24 | 81 ± 20 | 91 ± 22 | 0.493 |
| FVC, % of predicted value | |||||
| Pre–β2-agonist use | 86 ± 22 | 85 ± 22 | 86 ± 18 | 96 ± 19 | 0.09 |
| Post–β2-agonist use | 91 ± 20 | 90 ± 20 | 88 ± 18 | 97 ± 18 | 0.28 |
| FEV1/FVC | |||||
| Pre–β2-agonist use | 0.77 ± 0.62 | 0.67 ± 0.13 | 0.70 ± 0.11 | 0.72 ± 0.10 | 0.13 |
| Post–β2-agonist use | 0.79 ± 0.50 | 0.70 ± 0.13 | 0.72 ± 0.12 | 0.80 ± 0.10 | 0.06 |
| BDR, % | 2 ± 6.2 | 12 ± 12 | 9 ± 13 | 6 ± 7 | 0.03 |
| FeNO, ppb | 20 ± 9.7 | 53 ± 43 | 52 ± 42 | 38 ± 27 | 0.04 |
Definition of abbreviations: BDR = bronchodilator response; FeNO = exhaled nitric oxide; TEA = transcriptomic endotypes of asthma; YCAAD = Yale Center for Asthma and Airway Diseases.
Data are means ± SD. P values for comparisons among TEA clusters were determined using Kruskal-Wallis or Cochran-Armitage test. The false discovery rate estimated by the permutation-based method is 5.6%.